OncoSec Medical Inc (ONCSQ)

[dangerM]

Oncosec's multigene-construct / FLT3-ligand

just something interesting to note, other news from the AACR2018: someone has posted quite a comprehensive set of slides (all slides?) on a combo of low-dose radiation with an FLT3-ligand.

Just a small sample (n=9, eligibility criteria: 2nd line, stage 3 or 4 NSCLC "not amenable to curative therapy") and a questionable short observation period (endpoint: progression free survival at 4 weeks).

However, IMHO it shows that Flt3 might be an really interesting choice!

Ohry - FLT3 ligand (CDX-301) and stereotactic radiotherapy for advanced non-small cell lung cancer #AACR18 1/x https://t.co/QhZhrlVNfa pic.twitter.com/d8lAQGj1w4

— Bertrand Delsuc (@BertrandBio) April 15, 2018